Perspective Therapeutics reports 50% response rate in highest-dose cohort of VMT-α-NET trial
Bitget2026/10/23 14:50- Perspective Therapeutics announced interim Phase 1/2a results showing tumor responses and sustained disease control with VMT-α-NET in advanced SSTR2-positive neuroendocrine tumors.
- Results are being presented at the ESMO Congress 2026 in Madrid, running October 23-27.
- No dose-limiting toxicities or adverse event-related treatment discontinuations were reported; some patients experienced severe side effects, including kidney events.
- Phase 3 site preparations are targeted for completion around year-end 2026, with trial initiation expected in 2027 following FDA alignment.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SQM.US Q3 profit misses expectations; lithium price declines but demand outlook remains “encouraging”
SQM.US still reports seeing "encouraging" potential demand trends.
Mizuho: Consecutive system outages in the US trigger stockpiling surge! With short-term demand boosted, Costco (COST.US) sales momentum is expected to remain strong.
According to a report by Mizuho Securities analysts, following a series of recent system failures in the United States, consumers have started stockpiling essential goods, leading to a short-term surge in demand for Costco, a members-only retailer.

Biogen (BIIB.US) announces mid-stage trial data for early Alzheimer's candidate drug diranersen: significant slowing of clinical decline over two years
Biogen has released the latest interim clinical trial data for its early-stage Alzheimer's disease candidate drug, diranersen.

Nvidia Acting CEO Kress Reassures the Market: No Customer Loss and No Employee Exodus
Nvidia released its first quarterly financial report since Jensen Huang's resignation, after which Colette Kress told the media that major client demand has not been affected and the workforce remains stable, emphasizing that "everything is business as usual." The company's share price rose over 3% after hours, though the stock is still down 24% for the month.